Your browser doesn't support javascript.
loading
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.
Ho, Jingshan; Heong, Valerie; Peng Yong, Wei; Soo, Ross; Ean Chee, Cheng; Wong, Andrea; Sundar, Raghav; Liang Thian, Yee; Gopinathan, Anil; Yan Pang, Mei; Koe, Priscillia; Nathan Jeraj, Santhiay; Pyar Soe, Phyu; Yar Soe, Mu; Tang, Tiffany; Ng, Matthew C H; Tai, David W M; Tan, Tira J Y; Xu, Hongmei; Chang, Hua; Landesman, Yosef; Shah, Jatin; Shacham, Sharon; Chin Lee, Soo; Tan, Daniel S W; Cher Goh, Boon; Tan, David S P.
Affiliation
  • Ho J; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Heong V; Department of Medical Oncology, Tan Tock Seng Hospital, Singapore.
  • Peng Yong W; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Soo R; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Ean Chee C; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Wong A; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Sundar R; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Liang Thian Y; Department of Radiology, National University Hospital, Singapore.
  • Gopinathan A; Department of Radiology, National University Hospital, Singapore.
  • Yan Pang M; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Koe P; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Nathan Jeraj S; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Pyar Soe P; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Yar Soe M; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore.
  • Tang T; Department of Haematology-Oncology, National Cancer Centre, Singapore.
  • Ng MCH; Department of Haematology-Oncology, National Cancer Centre, Singapore.
  • Tai DWM; Department of Haematology-Oncology, National Cancer Centre, Singapore.
  • Tan TJY; Department of Haematology-Oncology, National Cancer Centre, Singapore.
  • Xu H; Karyopharm Therapeutics, Newton, MA, USA.
  • Chang H; Karyopharm Therapeutics, Newton, MA, USA.
  • Landesman Y; Karyopharm Therapeutics, Newton, MA, USA.
  • Shah J; Karyopharm Therapeutics, Newton, MA, USA.
  • Shacham S; Karyopharm Therapeutics, Newton, MA, USA.
  • Chin Lee S; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Tan DSW; Department of Haematology-Oncology, National Cancer Centre, Singapore.
  • Cher Goh B; Department of Haematology and Oncology, National University Cancer Institute Singapore, Singapore Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Tan DSP; Department of Haematology and Oncology, National University Cancer Institute, NUHS Tower Block, Level 7, 1E Kent Ridge Road, Singapore 119228.
Ther Adv Med Oncol ; 14: 17588359221087555, 2022.
Article in En | MEDLINE | ID: mdl-35432603
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Adv Med Oncol Year: 2022 Type: Article Affiliation country: Singapore
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Ther Adv Med Oncol Year: 2022 Type: Article Affiliation country: Singapore